MARCH 13: Due to the ever-evolving impact of the coronavirus pandemic, FARF staff will be working remotely for the next few weeks. While we are equipped with the necessary technology to continue meeting our mission and providing service, this will...
Announcements
Read about Dr. D'Andrea's FARF-funded research projects At the 2019 FARF Scientific Symposium, Dr. D’Andrea was presented with the Lifetime Achievement Award for dedicating his career to the advancement of Fanconi anemia research. Dr. D’Andrea has been a pillar of...
Announcements
Fanconi anemia (FA) is associated with progressive bone marrow failure, cancer predisposition, and multiple congenital abnormalities. Brain atrophy and other abnormalities of the brain have also been reported, although the cause of these abnormalities and recommendations for clinical care are...
Announcements
Aldehydes, including acetaldehyde and formaldehyde, can cause DNA damage by inducing DNA interstrand crosslinks, which cause damage to hematopoietic stem cells, leading to bone marrow failure and cancer in people with Fanconi anemia (FA). Exposure to aldehydes is inevitable and...
Announcements
Pilot Study on Metformin A National Institutes of Health program project grant on Fanconi anemia (FA) led by Dr. Markus Grompe at Oregon Health & Science University identified that metformin (a drug approved by the FDA to treat type II...
Announcements
Fanconi anemia (FA) is a hereditary disorder with a high predisposition to cancer, especially leukemia and squamous cell carcinoma (SCC). Head and neck squamous cell carcinoma (HNSCC) is the most common SCC diagnosed in people with FA. Diagnosis typically occurs...
Announcements
